CS2164, a novel multi‐target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti‐tumor potency

Although inhibitors targeting tumor angiogenic pathway have provided improvement for clinical treatment in patients with various solid tumors, the still very limited anti‐cancer efficacy and acquired drug resistance demand new agents that may offer better clinical benefits. In the effort to find a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, You, Shan, Song, Li, Zhi‐Bin, Xin, Li‐Jun, Pan, De‐Si, Yang, Qian‐Jiao, Liu, Ying‐Ping, Yue, Xu‐Peng, Liu, Xiao‐Rong, Gao, Ji‐Zhou, Zhang, Jin‐Wen, Ning, Zhi‐Qiang, Lu, Xian‐Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378272/
https://www.ncbi.nlm.nih.gov/pubmed/28004478
http://dx.doi.org/10.1111/cas.13141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378272/
https://www.ncbi.nlm.nih.gov/pubmed/28004478
http://dx.doi.org/10.1111/cas.13141

Ejemplares similares